IXICO PLC lands third Huntington’s disease contract in two months
Neuroimaging specialist IXICO PLC (AIM:IXI, OTC:PHYOF) has won its third Huntington’s disease (HD) contract in the space of two months.
He is part of a consortium of biopharmaceutical companies and charities developing imaging biomarkers (telltale signs) that could lead to the early detection of degenerative brain disease.
The contract, worth around £900,000, will see IXICO deliver its analysis through its deep learning-based IXIQ.Ai platform.
The data will allow researchers to stratify (sort) HD patients into certain groups while helping pharmaceutical companies understand the effectiveness of potential new treatments.
“Applying the latest image analysis and artificial intelligence techniques to this vast HD natural history dataset will allow us to create new insights and standards for implementing precision medicine approaches. in HD trials that we believe will be of great value to the HD community,” said IXICO CEO Giulio Cerroni.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that nothing posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is…
In exchange for the publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Site Content, the Company receives from said issuer…
FOR OUR FULL DISCLAIMER, CLICK HERE